Venus Remedies Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ashutosh Jain

Chief Executive Officer (CEO)

₹7.1m

Compensación total

Porcentaje del salario del CEO	97.0%
Permanencia del CEO	17.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	9.6yrs

Actualizaciones recientes de la dirección

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17

Recent updates

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Sep 17

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Jun 14

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Jun 13

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 14

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Mar 30

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Feb 24

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Feb 01

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Nov 16

Venus Remedies Limited's (NSE:VENUSREM) Stock Is Going Strong: Have Financials A Role To Play?

Mar 11

We Think Venus Remedies (NSE:VENUSREM) Is Taking Some Risk With Its Debt

Jan 14

Does Venus Remedies's (NSE:VENUSREM) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 23

Is Venus Remedies (NSE:VENUSREM) A Risky Investment?

Sep 22

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ashutosh Jain en comparación con los beneficios de Venus Remedies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	₹285m
Mar 31 2024	₹7m	₹7m	₹285m
Dec 31 2023	n/a	n/a	₹290m
Sep 30 2023	n/a	n/a	₹255m
Jun 30 2023	n/a	n/a	₹209m
Mar 31 2023	₹7m	₹7m	₹266m
Dec 31 2022	n/a	n/a	₹157m
Sep 30 2022	n/a	n/a	₹181m
Jun 30 2022	n/a	n/a	₹359m
Mar 31 2022	₹7m	₹7m	₹407m
Dec 31 2021	n/a	n/a	₹756m
Sep 30 2021	n/a	n/a	₹816m
Jun 30 2021	n/a	n/a	₹715m
Mar 31 2021	₹4m	₹4m	₹618m
Dec 31 2020	n/a	n/a	₹213m
Sep 30 2020	n/a	n/a	₹87m
Jun 30 2020	n/a	n/a	-₹40m
Mar 31 2020	₹3m	₹3m	-₹100m
Dec 31 2019	n/a	n/a	-₹161m
Sep 30 2019	n/a	n/a	-₹269m
Jun 30 2019	n/a	n/a	-₹269m
Mar 31 2019	₹3m	₹3m	-₹286m
Mar 31 2018	₹3m	₹3m	-₹307m

Compensación vs. Mercado: La compensación total de Ashutosh($USD80.71K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD37.72K).

Compensación vs. Ingresos: La compensación de Ashutosh ha sido consistente con los resultados de la empresa en el último año.

CEO

Ashutosh Jain (47 yo)

17.3yrs

Permanencia

₹7,145,217

Compensación

Mr. Ashutosh Jain, B.A., LL B serves as Chief Executive Officer at Venus Remedies Limited. He has been an Whole-Time Director of Venus Remedies Limited since May 2007 and serves as its Head of Legal, Regul...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pawan Chaudhary	Chairman	14.9yrs	₹12.77m	12.82% ₹ 578.1m
Ashutosh Jain	CEO, Head of Legal	no data	₹7.15m	sin datos
Manu Chaudhary	Joint MD	no data	₹12.53m	11.73% ₹ 528.9m
Akshansh Chaudhary	CTO & Executive Time Director	3.6yrs	₹5.19m	0.000010% ₹ 450.9
Peeyush Jain	Deputy MD	no data	₹7.69m	0.00037% ₹ 16.7k
Ajeet Kapoor	AVP of Accounts & Head CAAR Division	no data	sin datos	sin datos
Jitendra Singh	Chief General Manager of Administration	no data	sin datos	sin datos
Neha Kodan	Company Secretary & Compliance Officer	13.4yrs	sin datos	sin datos
Manav Soni	Senior Vice President of Plant & Commercial	4.7yrs	sin datos	sin datos
Rakesh Pandita	Chief General Manager of Secretarial & Banking	3.6yrs	sin datos	sin datos
Saransh Chaudhary	CEO of VMRC	3.6yrs	sin datos	sin datos
Aditi Chaudhary	President International Business	1.6yrs	sin datos	sin datos

3.6yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VENUSREM se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pawan Chaudhary	Chairman	14.9yrs	₹12.77m	12.82% ₹ 578.1m
Ashutosh Jain	CEO, Head of Legal	17.3yrs	₹7.15m	sin datos
Manu Chaudhary	Joint MD	18.9yrs	₹12.53m	11.73% ₹ 528.9m
Akshansh Chaudhary	CTO & Executive Time Director	2.3yrs	₹5.19m	0.000010% ₹ 450.9
Peeyush Jain	Deputy MD	no data	₹7.69m	0.00037% ₹ 16.7k
Gilbert Wenzel	Independent Non-Executive Director	18.8yrs	sin datos	sin datos
Suresh Chadha	Independent Non-Executive Director	18.8yrs	₹80.00k	sin datos
Jagdish Sharma	Non-Executive Independent Director	less than a year	sin datos	sin datos
Navdeep Sud	Independent Non-Executive Director	4.3yrs	₹80.00k	sin datos
Savita Gupta	Independent Non-Executive Director	no data	₹50.00k	sin datos
NPS Monga	Independent Non-Executive Director	1.3yrs	sin datos	sin datos
Anil Kumar	Independent Non-Executive Director	less than a year	sin datos	sin datos

9.6yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de VENUSREM se considera experimentada (9.6 años de antigüedad promedio).

Venus Remedies Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Venus Remedies Limited Announces Executive Appointments

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Venus Remedies Limited, Annual General Meeting, Sep 23, 2024

Venus Remedies Limited, Annual General Meeting, Aug 24, 2023

Less than half of directors are independent

Venus Remedies Limited, Annual General Meeting, Aug 23, 2022

Recent updates

Venus Remedies Limited Announces Executive Appointments

Shareholders May Not Be So Generous With Venus Remedies Limited's (NSE:VENUSREM) CEO Compensation And Here's Why

Venus Remedies Limited to Report Q2, 2025 Results on Nov 14, 2024

Venus Remedies Limited, Annual General Meeting, Sep 23, 2024

First quarter 2025 earnings released: EPS: ₹0.92 (vs ₹0.88 in 1Q 2024)

Venus Remedies Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 24% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

Venus Remedies Limited (NSE:VENUSREM) Held Back By Insufficient Growth Even After Shares Climb 26%

Now 27% overvalued after recent price rise

Venus Remedies (NSE:VENUSREM) Could Easily Take On More Debt

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹21.31 (vs ₹19.87 in FY 2023)

Venus Remedies Limited to Report Q4, 2024 Results on May 30, 2024

Investor sentiment improves as stock rises 16%

Venus Remedies Limited (NSE:VENUSREM) Not Doing Enough For Some Investors As Its Shares Slump 26%

Third quarter 2024 earnings released: EPS: ₹5.13 (vs ₹2.46 in 3Q 2023)

Venus Remedies Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings released: EPS: ₹7.44 (vs ₹3.99 in 2Q 2023)

Investor sentiment improves as stock rises 23%

Calculating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Venus Remedies Limited to Report Q2, 2024 Results on Nov 09, 2023

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Now 20% undervalued after recent price drop

Venus Remedies Limited Receives Marketing Approval from the Philippines for Six Key Chemotherapy Drugs

Investor sentiment deteriorates as stock falls 15%

New minor risk - Profit margin trend

Venus Remedies Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: EPS: ₹19.87 (vs ₹30.86 in FY 2022)

Venus Remedies Limited, Annual General Meeting, Aug 24, 2023

Investor sentiment improves as stock rises 15%

Venus Remedies Limited Receives Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities

Venus Remedies (NSE:VENUSREM) Seems To Use Debt Rather Sparingly

Full year 2023 earnings released: EPS: ₹19.88 (vs ₹30.86 in FY 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 20%

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ₹2.46 (vs ₹4.22 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ₹3.99 (vs ₹17.32 in 2Q 2022)

First quarter 2023 earnings released: EPS: ₹5.16 (vs ₹8.86 in 1Q 2022)

Venus Remedies Limited to Report Q2, 2023 Results on Nov 14, 2022

Venus Remedies Limited, Annual General Meeting, Aug 23, 2022

Venus Remedies Limited to Report Q1, 2023 Results on Jul 30, 2022

Now 21% undervalued after recent price drop

Estimating The Fair Value Of Venus Remedies Limited (NSE:VENUSREM)

Now 25% undervalued after recent price drop

Chairman recently bought ₹28m worth of stock

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Now 19% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹30.86 (vs ₹50.05 in FY 2021)

Venus Remedies Limited Appoints Akshansh Chaudhary as Additional Director (Whole Time Director)

Investor sentiment improved over the past week

Venus Remedies Limited to Report Q4, 2022 Results on May 27, 2022

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Venus Remedies (NSE:VENUSREM) Passed With Ease

Why Investors Shouldn't Be Surprised By Venus Remedies Limited's (NSE:VENUSREM) 25% Share Price Plunge

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Is Venus Remedies (NSE:VENUSREM) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Here's Why We Think Venus Remedies (NSE:VENUSREM) Is Well Worth Watching

Second quarter 2022 earnings released: EPS ₹17.32 (vs ₹10.55 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS ₹8.86 (vs ₹6.08 in 1Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹50.04 (vs ₹8.10 loss in FY 2020)

Venus Remedies Limited announced that it has received INR 137.52425 million in funding